On December 31, 2024, Orbimed Advisors LLC executed a notable transaction involving ADC Therapeutics SA, a Switzerland-based biotechnology company. The firm red
On December 11, 2024, Redmile Group, LLC (Trades, Portfolio), a prominent investment firm, significantly increased its stake in ADC Therapeutics SA by acquiring
ADC Therapeutics (ADCT) stock plunged 36% after the company reported data from a Phase 1b study of its drug Zynlonta in combination with Columvi for diffuse large B-cell lymphoma.
ADC Therapeutics SA (ADCT) Wednesday reported positive initial data from the LOTIS-7 Phase 1b study evaluating Zynlonta in combination with Genentech's Columvi for the treatment of Diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
Compugen Ltd (CGEN), a clinical-stage therapeutic discovery and development company, saw its stock rise by 5% to $1.66 with a trading volume of 315,350 shares.
PR NewswireLAUSANNE, Switzerland, Dec. 6, 2024
Company to host corporate update webcast to share results on December 11, 2024LAUSANNE, Switzerland, Dec. 6,
PR NewswireSHANGHAI, Nov. 28, 2024
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the
Loading... Loading...
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday.
Shares of BioNTech SE BNTX fell sha...
ADC Therapeutics SA ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and